The future of colonoscopy
PolypAID™ - the next generation colonoscopy guidance platform.
PolypAID™
A medical technology platform intended to assist endoscopists by aiding the detection of adenomas, sessile serrated lesions, and hyperplastic polyps in the colon.
Read moreAbout us
Augere Medical is commercializing the PolypAID™ platform for AI assisted colonoscopies with focus on quality, agility and delivering results.
Read more
Investors
So far, Augere has raised NOK 73 million (USD 6.6M) of which 36% come from public grants and 64% from private investors. The public grants originates from the Research Council of Norway, Innovation Norway and “Skattefunn”. The largest investors are AM Equity, MP Pensjon, Simula Innovation, and Farvatn Venture, who collectively own 80% of the share capital. The remaining shares are held by smaller shareholders and employees.
The company has implemented an options programme where all employees are granted options based on their seniority and contributions. This options programme amounts to 8% of the ordinary share capital, bringing the employees’ total share of the company on a fully diluted basis to 10.2%.
Partners
We can’t do this alone. We need to work with the leading hospitals, governments, and public health gurus. For additional information about Augere, send us a mail , and we’d be delighted to pick up the conversation.
post@augere.md
